BIOGENED S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18 PLN | +0.56% |
|
-11.76% | -.--% |
| Sales 2021 | 65.32M 16.6M | Sales 2022 | 79.62M 20.23M | Capitalization | 31.2M 7.93M |
|---|---|---|---|---|---|
| Net income 2021 | 1M 254K | Net income 2022 | 3M 762K | EV / Sales 2021 | 0.53 x |
| Net Debt 2021 | 13.74M 3.49M | Net Debt 2022 | 19.52M 4.96M | EV / Sales 2022 | 0.64 x |
| P/E ratio 2021 |
10.8
x | P/E ratio 2022 |
9.23
x | Employees | 205 |
| Yield 2021 * |
-
| Yield 2022 |
3.15% | Free-Float | 5.89% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.56% | ||
| 1 week | -11.76% | ||
| 1 month | -28.57% | ||
| 3 months | -33.33% | ||
| 6 months | +4.65% |
1 week
16.70
21.60
1 month
16.2026.60
Current year
16.2032.60
1 year
13.5032.60
3 years
6.2032.60
5 years
6.2032.60
10 years
5.0032.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 11-11-02 | |
| Director of Finance/CFO | 62 | - | |
| Chairman | 82 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 11-11-02 | |
| Chairman | 82 | 06-12-31 | |
| Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 18 | +0.56% | 174 |
| 24-05-29 | 17.9 | -0.56% | 1,690 |
| 24-05-28 | 18 | -0.55% | 729 |
| 24-05-27 | 18.1 | -11.27% | 2,827 |
| 24-05-24 | 20.4 | +6.81% | 492 |
End-of-day quote Warsaw S.E., May 30, 2024
More quotes
Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Companyâs product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 11.22M | |
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +16.12% | 14B | |
| +45.12% | 12.06B | |
| -9.58% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- BGD Stock
